MovDisordV3, Main, Exploration, bibRecord, 004315

Randomised, double‐blind, placebo‐controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia

Identifieur interne : 004315 ( Main/Exploration ); précédent : 004314; suivant : 004316

Randomised, double‐blind, placebo‐controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia

Auteurs : Susan H. Fox [Royaume-Uni] ; Mark Kellett [Royaume-Uni] ; A. Peter Moore [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni]

Source :

Movement Disorders [ 0885-3185 ] ; 2002-01.

RBID : ISTEX:820A66911789DED586603BDE2C38BCABB5D36D7C

Descripteurs français

Pascal (Inist)
- Adulte, Agoniste, Chimiothérapie, Dystonie, Essai clinique phase II, Essai croisé, Etude double insu, Nabilone, Pallidum, Pronostic, Randomisation, Récepteur cannabinoïde, Torsion, Traitement.
Wicri :
- topic : Adulte.

English descriptors

KwdEn :
- Adult, Aged, Agonist, Anti-Anxiety Agents (pharmacology), Anti-Anxiety Agents (therapeutic use), Cannabinoid receptor, Chemotherapy, Cross-Over Studies, Crossover study, Double blind study, Double-Blind Method, Dronabinol (analogs & derivatives), Dronabinol (pharmacology), Dronabinol (therapeutic use), Dystonia, Dystonia (physiopathology), Dystonia (therapy), Female, Globus Pallidus (drug effects), Globus Pallidus (physiopathology), Humans, Male, Middle Aged, Nabilone, Pallidum, Phase II trial, Prognosis, Randomization, Receptors, Cannabinoid, Receptors, Drug (drug effects), Torsion, Treatment, cannabis, dystonia, globus pallidus.
MESH :
- chemical , analogs & derivatives : Dronabinol.
- chemical , drug effects : Receptors, Drug.
- chemical , pharmacology : Anti-Anxiety Agents, Dronabinol.
- chemical , therapeutic use : Anti-Anxiety Agents, Dronabinol.
- drug effects : Globus Pallidus.
- physiopathology : Dystonia, Globus Pallidus.
- therapy : Dystonia.
- Adult, Aged, Cross-Over Studies, Double-Blind Method, Female, Humans, Male, Middle Aged, Receptors, Cannabinoid.

Abstract

Cannabis may have medicinal uses in a variety of diseases. The neural mechanisms underlying dystonia involve abnormalities within the basal ganglia—in particular, overactivity of the lateral globus pallidus (GPl). Cannabinoid receptors are located presynaptically on GABA terminals within the GPi, where their activation reduces GABA reuptake. Cannabinoid receptor stimulation may thus reduce overactivity of the GPl and thereby reduce dystonia. A double‐blind, randomised, placebo‐controlled, crossover study using the synthetic cannabinoid receptor agonist nabilone in patients with generalised and segmental primary dystonia showed no significant reduction in dystonia following treatment with nabilone. © 2001 Movement Disorder Society.

Url:

https://api.istex.fr/document/820A66911789DED586603BDE2C38BCABB5D36D7C/fulltext/pdf

DOI: 10.1002/mds.1280

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Randomised, double‐blind, placebo‐controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia</title>
<author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name>
</author>
<author><name sortKey="Kellett, Mark" sort="Kellett, Mark" uniqKey="Kellett M" first="Mark" last="Kellett">Mark Kellett</name>
</author>
<author><name sortKey="Moore, A Peter" sort="Moore, A Peter" uniqKey="Moore A" first="A. Peter" last="Moore">A. Peter Moore</name>
</author>
<author><name sortKey="Crossman, Alan R" sort="Crossman, Alan R" uniqKey="Crossman A" first="Alan R." last="Crossman">Alan R. Crossman</name>
</author>
<author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:820A66911789DED586603BDE2C38BCABB5D36D7C</idno>
<date when="2002" year="2002">2002</date>
<idno type="doi">10.1002/mds.1280</idno>
<idno type="url">https://api.istex.fr/document/820A66911789DED586603BDE2C38BCABB5D36D7C/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">003166</idno>
<idno type="wicri:Area/Istex/Curation">003166</idno>
<idno type="wicri:Area/Istex/Checkpoint">002C06</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Fox S:randomised:double:blind</idno>
<idno type="wicri:Area/Main/Merge">006320</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:02-0204560</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002843</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000478</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002630</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Fox S:randomised:double:blind</idno>
<idno type="wicri:Area/Main/Merge">006669</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:11835452</idno>
<idno type="wicri:Area/PubMed/Corpus">003B86</idno>
<idno type="wicri:Area/PubMed/Curation">003B86</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003958</idno>
<idno type="wicri:Area/Ncbi/Merge">000665</idno>
<idno type="wicri:Area/Ncbi/Curation">000665</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000665</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Fox S:randomised:double:blind</idno>
<idno type="wicri:Area/Main/Merge">006132</idno>
<idno type="wicri:Area/Main/Curation">004315</idno>
<idno type="wicri:Area/Main/Exploration">004315</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Randomised, double‐blind, placebo‐controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia</title>
<author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Walton Centre for Neurology and Neurosurgery, Liverpool</wicri:regionArea>
<wicri:noRegion>Liverpool</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kellett, Mark" sort="Kellett, Mark" uniqKey="Kellett M" first="Mark" last="Kellett">Mark Kellett</name>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Walton Centre for Neurology and Neurosurgery, Liverpool</wicri:regionArea>
<wicri:noRegion>Liverpool</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Current Address: Department of Neurology, Hope Hospital, Stott Lane, Salford, Manchester M6 7HD</wicri:regionArea>
<wicri:noRegion>Manchester M6 7HD</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Moore, A Peter" sort="Moore, A Peter" uniqKey="Moore A" first="A. Peter" last="Moore">A. Peter Moore</name>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Walton Centre for Neurology and Neurosurgery, Liverpool</wicri:regionArea>
<wicri:noRegion>Liverpool</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Crossman, Alan R" sort="Crossman, Alan R" uniqKey="Crossman A" first="Alan R." last="Crossman">Alan R. Crossman</name>
<affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Manchester Movement Disorders Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, and Motac Neuroscience Ltd., Manchester Incubator Building, Manchester</wicri:regionArea>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
</placeName>
<orgName type="university">Université de Manchester</orgName>
</affiliation>
</author>
<author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name>
<affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Manchester Movement Disorders Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, and Motac Neuroscience Ltd., Manchester Incubator Building, Manchester</wicri:regionArea>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
</placeName>
<orgName type="university">Université de Manchester</orgName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>John Wiley & Sons, Inc.</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2002-01">2002-01</date>
<biblScope unit="vol">17</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="145">145</biblScope>
<biblScope unit="page" to="149">149</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">820A66911789DED586603BDE2C38BCABB5D36D7C</idno>
<idno type="DOI">10.1002/mds.1280</idno>
<idno type="ArticleID">MDS1280</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Agonist</term>
<term>Anti-Anxiety Agents (pharmacology)</term>
<term>Anti-Anxiety Agents (therapeutic use)</term>
<term>Cannabinoid receptor</term>
<term>Chemotherapy</term>
<term>Cross-Over Studies</term>
<term>Crossover study</term>
<term>Double blind study</term>
<term>Double-Blind Method</term>
<term>Dronabinol (analogs & derivatives)</term>
<term>Dronabinol (pharmacology)</term>
<term>Dronabinol (therapeutic use)</term>
<term>Dystonia</term>
<term>Dystonia (physiopathology)</term>
<term>Dystonia (therapy)</term>
<term>Female</term>
<term>Globus Pallidus (drug effects)</term>
<term>Globus Pallidus (physiopathology)</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Nabilone</term>
<term>Pallidum</term>
<term>Phase II trial</term>
<term>Prognosis</term>
<term>Randomization</term>
<term>Receptors, Cannabinoid</term>
<term>Receptors, Drug (drug effects)</term>
<term>Torsion</term>
<term>Treatment</term>
<term>cannabis</term>
<term>dystonia</term>
<term>globus pallidus</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Dronabinol</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Drug</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Anti-Anxiety Agents</term>
<term>Dronabinol</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Anxiety Agents</term>
<term>Dronabinol</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Globus Pallidus</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Dystonia</term>
<term>Globus Pallidus</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Dystonia</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Cross-Over Studies</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Receptors, Cannabinoid</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Adulte</term>
<term>Agoniste</term>
<term>Chimiothérapie</term>
<term>Dystonie</term>
<term>Essai clinique phase II</term>
<term>Essai croisé</term>
<term>Etude double insu</term>
<term>Nabilone</term>
<term>Pallidum</term>
<term>Pronostic</term>
<term>Randomisation</term>
<term>Récepteur cannabinoïde</term>
<term>Torsion</term>
<term>Traitement</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Adulte</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Cannabis may have medicinal uses in a variety of diseases. The neural mechanisms underlying dystonia involve abnormalities within the basal ganglia—in particular, overactivity of the lateral globus pallidus (GPl). Cannabinoid receptors are located presynaptically on GABA terminals within the GPi, where their activation reduces GABA reuptake. Cannabinoid receptor stimulation may thus reduce overactivity of the GPl and thereby reduce dystonia. A double‐blind, randomised, placebo‐controlled, crossover study using the synthetic cannabinoid receptor agonist nabilone in patients with generalised and segmental primary dystonia showed no significant reduction in dystonia following treatment with nabilone. © 2001 Movement Disorder Society.</div>
</front>
</TEI>
<affiliations><list><country><li>Royaume-Uni</li>
</country>
<region><li>Angleterre</li>
<li>Grand Manchester</li>
</region>
<settlement><li>Manchester</li>
</settlement>
<orgName><li>Université de Manchester</li>
</orgName>
</list>
<tree><country name="Royaume-Uni"><noRegion><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name>
</noRegion>
<name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name>
<name sortKey="Crossman, Alan R" sort="Crossman, Alan R" uniqKey="Crossman A" first="Alan R." last="Crossman">Alan R. Crossman</name>
<name sortKey="Kellett, Mark" sort="Kellett, Mark" uniqKey="Kellett M" first="Mark" last="Kellett">Mark Kellett</name>
<name sortKey="Kellett, Mark" sort="Kellett, Mark" uniqKey="Kellett M" first="Mark" last="Kellett">Mark Kellett</name>
<name sortKey="Moore, A Peter" sort="Moore, A Peter" uniqKey="Moore A" first="A. Peter" last="Moore">A. Peter Moore</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004315 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004315 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:820A66911789DED586603BDE2C38BCABB5D36D7C
   |texte=   Randomised, double‐blind, placebo‐controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Randomised, double‐blind, placebo‐controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia

Randomised, double‐blind, placebo‐controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.